Please assess the completion status of the following clinical trial:

Trial Title: Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male aged ≥ 35 years~* Type 2 diabetes mellitus~* Symptomatic PAD~* Ankle-brachial index ≤ 0.85 or calcified blood vessels with toe-brachial index ≤ 0.6 and/or abnormal post-exercise ankle-brachial index~* Prior surgical or percutaneous intervention of the peripheral arteries ≥12 months previously with a residual stenoses of ≥50% in a non-dilated artery.~Exclusion Criteria:~* Subject is pregnant or breast-feeding~* Planned revascularization or amputation~* Known bleeding disorder~* History of intracranial hemorrhag3~* Considered at risk of hemorrhagic events~* Hypersensitivity or allergic reactions to aspirin~* Concomitant use of anticoagulants such as warfarin, dabigatran, factor Xa inhibitors or antiplatelet drugs such as clopidogrel, dipyridamole and sulfapyridine~* Subject has a condition or circumstance which would prevent them from adhering to treatment regimens~* Subject has active infection~* Subject has an anemia~* Subject has given blood or received a blood transfusion at any point during the study~* Subject has polycythemia vera or any hyperviscosity syndrome~* Subjects with Waldenstrom's macroglobulinemia who have an increased risk of hyperviscosity syndrome~* Subject has history of severe liver disease, obstructive liver disease such as primary biliary cirrhosis or end-stage renal disease (eGFR \<30 mL/min/m2)~* Family members or employees of the investigator or study centers involved in the study~* Subject has poor diabetes or hypertension control (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin/Ticagrelor placebo (Type: PLACEBO_COMPARATOR): aspirin 81 mg daily and ticagrelor placebo twice daily
- Aspirin/Ticagrelor (Type: ACTIVE_COMPARATOR): aspirin 81 mg daily and ticagrelor 90 mg twice daily
- Aspirin Placebo/Ticagrelor (Type: ACTIVE_COMPARATOR): aspirin placebo daily and ticagrelor 90 mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).